Decay-accelerating factor modulates induction of T cell immunity by Heeger, Peter S. et al.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
JEM © The Rockefeller University Press $8.00
Vol. 201, No. 10, May 16, 2005 1523–1530 www.jem.org/cgi/doi/10.1084/jem.20041967
 
BRIEF DEFINITIVE REPORT
 
1523
 
Decay-accelerating factor modulates 
induction of T cell immunity
 
Peter S. Heeger,
 
1,2
 
 Peter N. Lalli,
 
1,2
 
 Feng Lin,
 
2
 
 Anna Valujskikh,
 
1
 
 Jinbo Liu,
 
2
 
 
 
Nasima Muqim,
 
2
 
 Yuanyuan Xu,
 
3
 
 and M. Edward Medof
 
2
 
1
 
Department of Immunology, Cleveland Clinic Foundation, Cleveland, OH 44195
 
2
 
Institute of Pathology, Case Western Reserve University, Cleveland, OH 44106
 
3
 
Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL 35294
 
Decay-accelerating factor (Daf) dissociates C3/C5 convertases that assemble on host cells and 
thereby prevents complement activation on their surfaces. We demonstrate that during primary 
T cell activation, the absence of Daf on antigen-presenting cells (APCs) and on T cells enhances 
T cell proliferation and augments the induced frequency of effector cells. The effect is factor 
D- and, at least in part, C5-dependent, indicating that local alternative pathway activation is 
essential. We show that cognate T cell–APC interactions are accompanied by rapid production of 
alternative pathway components and down-regulation of Daf expression. The findings argue that 
local alternative pathway activation and surface Daf protein function respectively as a 
costimulator and a negative modulator of T cell immunity and explain previously reported 
observations linking complement to T cell function. The results could have broad therapeutic 
implications for disorders in which T cell immunity is important.
 
Complement directly destroys invading patho-
gens and is a source of anaphylatoxins that attract
phagocytic cells to sites of insult (1). In adap-
tive immune responses, it is the effector system
for antibody-mediated immunity. Previous
studies have indicated that complement influ-
ences alloimmune, autoimmune, antiviral, and
antitumor T cell responses (2–5), but these ob-
servations remain largely unexplained. Because
protective antiviral and antitumor T cell reac-
tivity as well as T cell memory are highly de-
pendent on the size of the induced effector T
cell repertoire (6–8), clarifying how comple-
ment shapes the effector T cell repertoire has
broad biological and clinical implications.
Decay-accelerating factor (Daf) is a ubiqui-
tously expressed intrinsic complement-regulatory
protein whose function is to dissociate C3/C5
convertases on host-cell surfaces (9), thereby
limiting local C3a/C5a anaphylatoxin produc-
tion and C3b/C5b-initiated progression of the
cascade. Daf also has been identified as a ligand
for CD97, a leukocyte- and endothelial cell-
associated member of the epidermal growth
factor family of proteins, which has been iden-
tified as a Daf adhesin for attracting leukocytes
(10, 11). Although it is known that Daf, a gly-
cophosphatidylinositol-anchored protein (12,
13), is expressed in lipid rafts on T lympho-
cytes and can be found in the general proxim-
ity of the TCR complex (14, 15), no direct or
indirect role for Daf in controlling T cell immu-
nity has previously been described. Here we
report the unanticipated findings that Daf modu-
lates T cell immunity by controlling T cell– and
APC-induced alternative pathway C3 activa-
tion during cognate interactions.
 
RESULTS AND DISCUSSION
 
To address whether Daf influences cellular
immune responses, we studied splenocytes
obtained from mice made genetically defi-
cient in the 
 
Daf1
 
 gene (
 
Daf1
 
 
 
/
 
 
 
, 
 
H-2
 
b
 
) and
from 
 
Daf1
 
 
 
/
 
 
 
 littermates. Initial studies, using
mixed lymphocyte cultures in which 
 
H-2
 
b
 
Daf1
 
 
 
/
 
 
 
 or control 
 
Daf1
 
 
 
/
 
 
 
 spleen cells were
stimulated with allogeneic 
 
H-2
 
k
 
 spleen cells in
vitro, revealed that 
 
Daf1
 
 
 
/
 
 
 
 cells responded
more vigorously than did control 
 
Daf1
 
 
 
/
 
 
 
cells (Fig. 1 A). Reconstitution of 
 
Daf1
 
 
 
/
 
 
 
spleen cells with lipid-tailed mouse Daf pro-
tein attenuated the increased responsiveness
(Fig. 1, A and B), verifying that the effects
were specific to Daf deficiency. Substantiat-
ing this interpretation, the addition of anti-
Daf mAb 2C6 specifically increased the num-
ber of induced alloreactive, WT effector T
cells (Fig. 1 C).
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To differentiate antigen-induced versus bystander effects
of Daf inhibition on T cell activation, we performed studies
using TCR transgenic T cells. The frequency of peptide-
activated TCR transgenic Mar T cells (C57BL/6, 
 
H-2
 
b
 
,
 
RAG2
 
 
 
/
 
 
 
,
 
 specific for male antigen HY
 
Dby
 
) was similarly
increased in the presence of anti-Daf mAb but not of control
mAb (Fig. 1 C).
We next evaluated in vivo T cell responses induced to
the male antigen, HY. 
 
H-2
 
b
 
 female mice reject 
 
H-2
 
b
 
 male
skin grafts using T cells specific for class II MHC–restricted
HY
 
Dby
 
 and class I MHC–restricted HY
 
Uty
 
 (16). As shown
in Fig. 2 A, transplantation of 
 
Daf1
 
 
 
/
 
 
 
 females with 
 
Daf1
 
 
 
/
 
 
 
male skin grafts resulted in a 1.5- and threefold increased fre-
quency of anti-HY CD4 and CD8 T cells, respectively,
when compared with control 
 
Daf1
 
 
 
/
 
 
 
 females engrafted
with 
 
Daf1
 
 
 
/
 
 
 
 male skin. For the CD4 response, the absence
of Daf on either the donor or the recipient similarly en-
hanced T cell immunity; for the CD8 response, a greater ef-
fect was noted when the recipient was 
 
Daf1
 
 
 
/
 
 
 
 (Fig. 2 A).
The increased frequency of anti-HY T cells was associated
with a 2-d acceleration of graft destruction (median survival,
14 d for 
 
Daf1
 
 
 
/
 
 
 
 to 
 
Daf1
 
 
 
/
 
 
 
 vs. 12 d for 
 
Daf1
 
 
 
/
 
 
 
 to 
 
Daf1
 
 
 
/
 
 
 
,
 
Daf1
 
 
 
/
 
 
 
 to 
 
Daf1
 
 
 
/
 
 
 
, or 
 
Daf1
 
 
 
/
 
 
 
 to 
 
Daf1
 
 
 
/
 
 
 
; 
 
n
 
 
 
 
 
 4–8/
group; P 
 
 
 
 0.05). Similarly, alloreactive T cells in recipient
C3H mice (
 
H-2
 
k
 
) primed at 
 
 
 
10-fold higher frequencies to
allogeneic 
 
Daf1
 
 
 
/
 
 
 
 (8500 / 10
 
6
 
 anti-
 
H-2
 
b
 
 IFN
 
 
 
-producers)
versus 
 
Daf1
 
 
 
/
 
 
 
 (520/10
 
6
 
 anti-
 
H-2
 
b
 
 IFN
 
 
 
 producers; 
 
n
 
 
 
 
 
3/group; P 
 
 
 
 0.05) heart grafts.
We next immunized 
 
Daf1
 
 
 
/
 
 
 
 and control females with
the HY
 
Dby
 
 peptide and tested for recall responses at d 12
and d 30 (Fig. 2 B). At both time points, the frequency of
splenic HY
 
Dby
 
-specific IFN
 
 
 
 producers was significantly
higher in the 
 
Daf1
 
 
 
/
 
 
 
 mice. Immunization also induced
stronger responses to OVA
 
323-339
 
 and to MOG
 
35-55
 
 in 
 
Daf1
 
 
 
/
 
 
 
mice compared with controls (3–5-fold at 12 and 30 d after
immunization; unpublished data). In combination, these ex-
periments argued that T cell immunity induced by proin-
flammatory stimuli is augmented in the absence of Daf.
We next asked how APC-expressed (as opposed to T
cell-expressed) Daf affects T cell reactivity. 
 
H-2
 
b
 
 
 
Daf1
 
 
 
/
 
 
 
splenic stimulators primed approximately sixfold higher fre-
quencies of alloreactive IFN
 
 
 
-secreting C3H (
 
H-2
 
k
 
) effector
Figure 1. Daf deficiency/blockade augments cellular immunity in 
vitro. (A) IFN  ELISPOT assays for Daf1 /  splenocytes (  reconstitution 
using lipid-tailed murine rDaf) or Daf1 /  splenocytes versus allogeneic 
H-2k spleen cells. (B) Flow cytometry of Daf expression levels on cells in A. 
(C) WT H-2k T cells stimulated with allogeneic H-2b spleen cells (left) or 
Mar TCR transgenic T cells stimulated with HYDby peptide-loaded H-2b 
APCs (right) with or without anti-Daf mAb 2C6 or control IgG in IFN  
ELISPOT assays. Means and SD (n   3–5/group) shown are representative 
of 2–4 independent experiments; *, P   0.05.JEM VOL. 201, May 16, 2005 1525
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T cells than control Daf1 /  H-2b spleen cells (Fig. 3 A).
This effect was abrogated by incorporation of recombinant
lipid-tailed mouse Daf onto the surface of the Daf1 / 
spleen cells (Fig. 3 A). Although these data were obtained
using APCs from mice backcrossed four generations to
C57BL/6, similar results were obtained using splenic APCs
from ninth-generation backcross Daf1 /  (101   18/105
C3H T cells) and Daf1 /  littermates (45   11/105 C3H T
cells; P   0.05). Responder C3H T cells also proliferated
more vigorously both in vitro and in vivo (Fig. 3, B and C)
when stimulated with allogeneic Daf1 /  APCs versus
Daf1 /  APCs. Female Mar T cells responded up to fivefold
more vigorously, both in vitro (Fig. 3 D) and in vivo (Fig. 3
E), when stimulated with male H-2b stimulator cells from
Daf1 /  mice than from Daf1 /  controls, confirming an
antigen-specific effect. Mar cells also responded at higher
frequency in vitro to splenic APCs from ninth-generation
backcross by 5,6-carboxy-2,7-dechlorofluorescein (CFSE)
proliferation (3.01% vs. 0.49% of Mar cells divided  2 times
in Daf1 /  vs. Daf1 / , respectively) and ELISPOT (127  
12 IFN  producers/104 cells with Daf1 /  APCs vs. 46   5
with Daf1 / APCs. P   0.05).
We next asked if the absence of Daf on T cells affects the
induced T cell immune response. As assessed by IFN 
ELISPOT (Fig. 4 A) or CFSE dilution (not depicted),
Daf1 /  T cells responded more vigorously than Daf1 / 
T cells to Daf1 /  allogeneic stimulator cells. Moreover,
Thy1.2  Daf1 /  T cells responded to in vivo immunization
more vigorously than Thy1.2  Daf1 /  T cells when the T
cells were transferred into congenic Thy1.1  Daf1 /  recip-
ients (the Thy1.1 and Thy1.2 antigens allowed differentia-
tion of the transferred T cells from the endogenous T cells;
Fig. 4 B). The effect was similar but smaller in magnitude
than when Daf protein was deficient on the APCs (Fig. 3).
To determine if the augmenting effect of Daf deficiency
relates to work published in the 1980s that Daf cross-linking
transmits a proliferative signal (17), we tested in vitro female
responses to HYDby. 5 d of in vitro culture with HYDby
peptide induced a significantly higher frequency of effector
IFN  producers from Daf1 /  splenocytes compared with
Daf1 /  spleen cells (52   9 vs. 13.8   4/200,000 spleen
cells; mean of n   4/group; P   0.05). Frequencies of HY-
Dby-reactive IFN  and IL-2 producers were identical ( 1
in 300,000) in naive Daf1 /  and Daf1 /  spleens at the start
of the culture. Thus, the enhanced T cell immunity must be
attributed to the absence of Daf and not to a Daf-transmitted
proliferative signal.
Because C3 deficiency has been found to limit T cell re-
activity in vivo (3, 5, 18), and because Daf’s known function
is to circumvent C3 deposition on host cells (1, 9), we inves-
tigated whether the enhanced T cell responsiveness gener-
ated in the absence of Daf could at least in part be mediated
via a C3-dependent process. Factor D is essential for assem-
bly of the alternative pathway C3 convertase (C3bBb; refer-
ence 1), which is dissociated by Daf (9). Splenocytes geneti-
cally deficient in factor D or doubly deficient in factor D and
Daf primed allogeneic IFN  producers at frequencies lower
or comparable to spleen cells obtained from Daf1 /  mice
(Fig. 3 A). The enhanced expansion either of polyclonal al-
logeneic T cells (Fig. 3 C) or Mar TCR transgenic T cells
(Fig. 3 E) in Daf1 /  male mice did not occur in vivo in
Figure 2. Deficiency of Daf protein augments cellular immunity in 
vivo. (A) IFN  ELISPOT assays were performed at rejection of male to female 
skin grafts ( / , Daf1 / ;  / , Daf1 / ) to assess reactivity to male pep-
tides HYDby (left) and HYUty (right). Each symbol represents an individual an-
imal (mean of triplicate wells, SD   15%). –, means for all animals per group 
(n   4–8); *, P   0.05 versus Daf1 /  to Daf1 / . No response ( 10 IFN  
producers/500,000 cells) was detected in any animal to control antigens 
OVA323-339 and  -gal96-103, and no responses were detected in naive mice 
(not depicted). (B) Spleen cell responses by IFN  ELISPOT 12 d (top) or 30 d 
(bottom) after immunization of Daf1 /  or Daf1 /  mice with HYDby peptide 
plus CFA. No response was detected to control antigens (not depicted). Means 
plus SD for three to five animals/group are shown. The results are fully repre-
sentative of two to four independent experiments. *, P   0.05.DECAY-ACCELERATING FACTOR MODULATES INDUCTION OF T CELL IMMUNITY | Heeger et al. 1526
Figure 3. Daf1 /  APCs augment T cell immunity in vitro and in 
vivo via alternative complement activation. (A) H-2k T cells mixed 
with allogeneic H-2b splenic stimulators with or without rDaf were 
tested in IFN  ELISPOT assays (means plus SD; n   3 replicates/group). 
(B) Proliferation of CFSE-labeled WT H-2k T cells versus allogeneic Daf1 /  
or Daf1 /  macrophages on d 5. The precursor frequencies of responding 
T cells were 1.01% (4.1% underwent more than three divisions) against 
Daf1 /  cells versus 0.07% against Daf1 /  cells (1.1% underwent more 
than three divisions). (C) Proliferation of splenic CFSE-labeled H-2k T 
cells on day 5 after injection into allogeneic hosts. The mean numbers of 
transferred cells that underwent more than three cell divisions (n   3 
animals/group) are shown. (D) IFN  ELISPOT production by Mar T cells 
stimulated with 10  M HYDby plus spleen cells. (E) Proliferation of 
CFSE-labeled V 6  Mar T cells 3 d after adoptive transfer into indicated 
mice (3   106 cells/mouse). (Left) representative plots gated on CFSE  
V 6  cells (inset: % Mar cells/spleen). (Right) quantified means (n   3 
animals/group). (F, left) Daf1 /  or Daf1 /  mice were immunized with 
OVA323-339 plus anti-C5 mAb or control (1 mg i.p. every other day), and 
recall assays to OVA323-339 (0.1  M) were performed by ELISPOT on d 16. 
*, P   0.05 versus the response in Daf1 /  mice. Right: 3-d in vitro IFN  
ELISPOT assays of H-2k T cells versus Daf1 /  or Daf1 /  APCs plus 100 
 g/ml anti-C5 mAb or control (top) or H-2k T cells versus Daf1 /  spleen 
cells plus recombinant C5a (bottom). *, P   0.05 versus control. Each 
result is representative of three individual experiments.JEM VOL. 201, May 16, 2005 1527
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male mice doubly deficient in Daf and factor D. Mar cells
responded similarly in factor D–deficient and WT males
(Fig. 3 D). In contrast, although CD97 is a ligand for Daf,
addition of blocking anti-CD97 mAb (11) had essentially no
effect on the induced frequency of effector T cells in an in
vitro assay (140–160 alloreactive IFN -producing T cells/
400,000 responders   0–10  g/ml anti-CD97 mAb 1B2 or
control; unpublished data).
Because the absence of Daf disables cell-surface C3 and C5
convertase regulatory activity, and because there is a report
that C5a can influence T cell immunity (19), we tested
whether C5 is involved in the enhanced T cell responsiveness.
As shown in Fig. 3 F, anti-C5 mAb partially abrogated the en-
hanced in vivo T cell responsiveness in Daf1 /  mice after im-
munization and partially blocked the augmented T cell alloim-
munity primed in vitro by Daf1 /  APCs. Addition of C5a to
in vitro cultures enhanced T cell responsiveness (Fig. 3 F).
Because of the previously described findings implicating
complement, we next evaluated synthesis of alternative path-
way complement components by T cells and APCs during
cognate interactions. We established an MLR in serum-free
medium, separated the T cells and APCs by flow sorting at
different time points, and performed quantitative RT-PCR
for C3, factor B, and factor D on each population. These
studies showed that both T cells and APCs markedly up-reg-
ulated synthesis of all three components within 1 h of inter-
action (Fig. 5 A). Similar results were detected when Mar
TCR transgenic T cells were stimulated with syngeneic
macrophages plus HYDby peptide (but not OVA323-339; un-
published data). In accordance with the increased gene ex-
pression, stimulation of Mar T cells with HYDby-peptide–
loaded macrophages induced C3 protein as detected by
immunoelectron microscopy (Fig. 5 B). Antigen-specific T
cell/APC mixing, as well as anti-CD3 stimulation of poly-
clonal T cells, generated C3, factor B, and factor D proteins
in serum-free culture supernatants as assessed by zymosan
C3b uptake assays (Fig. 5 C). Western blotting with specific
antibodies further verified the complement component pro-
duction by T cells as well as by APCs (Fig. 5 D).
Overall, our findings that (a) T cells proliferate into an
expanded number of effector cells in the absence of Daf, (b)
the effects of Daf deficiency are abrogated in the absence of
factor D, (c) the augmented responsiveness is reduced by
anti-C5 mAb, and (d) T cell responsiveness is increased by
C5a uncover an important role for complement and Daf as
modulators of T cell immunity.
The precise mechanisms by which APC- and/or T cell–
produced complement activation fragments participate in
costimulation remains to be characterized fully. Although
our data demonstrate a role for C5 (see Fig. 3 F) potentially
through C5a, a finding consistent with previous reports that
C5aR inhibition diminishes antiviral immunity (19), the
molecular basis of complement–T cell interactions may be
multifactorial. There are reports that CR1 blockade inhibits
in vitro T cell activation (20–22), and there are reports that
the absence of C3a receptor on APCs decreases Th1 immu-
nity (23). Deposited C3b or other complement split prod-
ucts during T cell–APC interactions also could stimulate T
cells during antigen-induced activation (21). Control experi-
ments have shown Daf deficiency does not affect surface ex-
pression of costimulatory molecules on CpG-activated mac-
rophages or DCs (unpublished data).
Enhanced T cell responsiveness in the absence of Daf po-
tentially has several implications. In addition to the acceler-
ated kinetics of rejection (Fig. 2), other studies have shown
that MOG35-55-induced experimental autoimmune encepha-
lomyelitis is more severe in Daf1 /  mice, indicating that
Daf may be important in T cell autoimmunity (unpublished
data). Our data reveal that the augmented immunity persists
for at least 30 d (Fig. 2), but we have not yet fully addressed
the longevity of the memory response.
Although our data generated in Daf1 /  mice implicate
that Daf is important in T cell responsiveness via effects on
complement activation, the physiological mechanism is not
established. Flow cytometric analysis showed down-regu-
lated surface expression of Daf on APCs during antigen-spe-
Figure 4. Daf deficiency on T cells enhances T cell responsiveness. 
(A) Purified T cells were mixed with WT allogeneic H-2k splenic stimulator 
cells in IFN  ELISPOT assays. (B) T cell–depleted WT Thy1.1 (H-2b) females 
were given adoptive transfers of 7.5   106 unfractionated, purified 
splenic T cells isolated from Thy1.2  Daf1 /  or Daf1 /  mice. The recon-
stituted hosts were immunized with HYDby plus CFA, and recall IFN  
ELISPOT assays (means plus SD; n   3/group) were performed 21 d later. 
Flow cytometry confirmed that all IFN  derived from the Thy1.2  cells 
(not depicted). *, P   0.05.DECAY-ACCELERATING FACTOR MODULATES INDUCTION OF T CELL IMMUNITY | Heeger et al. 1528
Figure 5. T cells and APCs produce complement components dur-
ing cognate interactions. (A) H-2k T cells were mixed with allogeneic 
peritoneal macrophages, flow sorted at predetermined time points, 
tested for complement expression by quantitative RT-PCR, and com-
pared with unstimulated controls. (B) Electron micrograph of immuno-
staining using gold–anti-C3 of Mar T cells mixed with female H-2b peri-
toneal macrophages plus HYDby peptide (top) or OVA323-339 (bottom). 
Note gold particles (arrowheads) only in the HYDby peptide-stimulated 
sample. T, T cell; M, macrophage. Bar, 200  m. (C) C3, factor B, and 
factor D in serum-free culture supernates of Mar T cells mixed with 
HYDby-loaded APCs overnight before (top) and after (middle) cell sort-
ing and reculturing for an additional 3 h. Data are plotted as relative 
increase over OVA323-339-stimulated controls. C3, factor B, and factor D 
in serum-free culture supernates of H-2k T cells stimulated overnight 
with anti-CD3 (bottom panel), expressed as fold increase over controls. 
(D) Western blots for factor B (fB, top) and C3 (bottom) in culture super-
natants of Mar T cells stimulated with WT or C3 /  splenic APCs and 
HYDby peptide or OVA323-339. Densitometry revealed 20% increase in C3 
and 175% increase in factor B with HYDby peptide versus OVA323-339. 
 , positive control (normal mouse serum); —, negative control (serum 
from fB / /Crry /  or C3 /  mice). E. Plots of Daf expression on macro-
phages at 0, 24, and 48 h after mixing with Mar T cells plus HYDby pep-
tide or OVA323-339. All results are representative of experiments per-
formed at least two or three times.JEM VOL. 201, May 16, 2005 1529
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cific, cognate interactions between Marilyn (Mar) T cells
and macrophages (see Fig. 5 E). These findings are consistent
with previously reported analyses (24) that, after superanti-
gen administration, isolated splenic T cell mRNAs for com-
mon T cell–signaling molecules were markedly increased at
8 h, but mRNA for Daf was decreased 10-fold.
In summary, in addition to providing a possible explana-
tion for previous reports (2–4, 6, 21, 23, 25), our data raise
the possibility that Daf expression could be genetically or
pharmacologically manipulated for therapeutic purposes.
MATERIALS AND METHODS
Mice. Daf1 /  (H-2b) mice and littermate controls backcrossed to C57BL/6
four or nine generations were produced as described previously (25). Fac-
tor D /  mice were intercrossed with the Daf1 /  mice. Female Mar-
Rag2 /  mice (H-2b; reference 26) were a gift from P. Matzinger (National
Institutes of Health, Bethesda, MD). Remaining mice were purchased from
Jackson ImmunoResearch Laboratories. Animals were used under approved
animal protocols. Skin graft transplantation was performed as described pre-
viously (27, 28).
IFN  ELISPOT assays. Cytokine-secreting spleen or purified T cells
( 93% CD3 ; columns obtained from R&D Systems) were quantified by
IFN  or IL-2 ELISPOT as described previously (27, 28) with or without
anti-C5 mAb (clone BB5.1; Alexion), anti-Daf mAb (25) (2C6; B.P. Mor-
gan, Cardiff University, Cardiff, Wales, UK), isotype control, or recombi-
nant mouse C5a (Cell Sciences). Daf expression was reconstituted on
Daf1 /  cells using a lipid-tailed Daf molecule (N-(myristoyl)GSSKSPS-
KKKKKKPGDC-(S-2-thiopyridyl) C-amide (R.A.G. Smith, Inflazyme
Pharmaceuticals, Richmond, BC, Canada) added to the free carboxyl-ter-
minal Cys of mouse Daf CCP1-4 (supplemental text is available at http://
www.jem.org/cgi/content/full/jem.20041967/DC1). Peptides were syn-
thesized by Research Genetics. In vitro experiments were performed in se-
rum-free HL-1 medium (Cambrex Bioproducts).
Proliferation assays. CFSE-stained T cells (27) were mixed with spleen
cells or thioglycollate-induced peritoneal macrophages. For in vivo stimula-
tion, 3   106 CFSE-labeled cells were injected into the tail vein of suble-
thally irradiated (400 rad) mice and analyzed 3 d later. The percentage of re-
sponding cells was calculated as described previously (27). All other
antibodies were obtained from BD Biosciences. Cells were stained (27, 28)
and analyzed on a Becton Dickinson FACScan.
In vivo T cell transfer and immunization. Female C57BL/6 Thy1.1
(Daf1 / ) mice CD4- and CD8-depleted with GK1.5/YTS 191 plus TIB
105/YTS 169.4 on days  3,  2, and  1. 7.5   106 Daf1 /  or Daf1 / 
(both Thy 1.2) T cells were adoptively transferred (tail vein) on day 0. Mice
were immunized on day 1 using 100  g of HYDby peptide in CFA.
Immunoelectron microscopy. Peritoneal macrophages were placed in
0.4- m tissue culture inserts (Becton Dickinson) in 24-well culture dishes
with Mar T cells at a 1:1 ratio, with or without HYDby peptide or control
OVA323-339 peptide at 10  g/ml. After fixation with 1% paraformaldehyde/
0.1% glutaraldehyde/PBS/0.05 M sucrose, samples were dehydrated, em-
bedded, sectioned, labeled with goat anti–mouse C3 (MP Biomedicals,
Inc.), and gold-labeled donkey anti–goat IgG (Jackson ImmunoResearch
Laboratories). Counterstaining was performed with lead citrate.
Quantitative analysis of complement components in T cells and
macrophages. Total RNA was extracted from the sorted populations of T
cells and macrophages (QIAGEN mini RNeasy kit) and reverse transcribed
by oligo dT primer with SuperscriptII reverse transcriptase (Invitrogen).
Real-time PCR was performed on an Applied Biosystems Prism 7700 Se-
quence Detection System with respective primers (available from author by
request). The average threshold cycle differences among the samples were
normalized against  -actin (control) in the corresponding cDNA preparation.
Complement assays. Supernates were obtained from overnight cultures
of purified T cells with or without anti-CD3 (2C11, 2  g/ml) or CFSE-
labeled Mar T cells plus peptide/APCs in serum-free medium. CFSE-labeled
Mar T cells were flow sorted and incubated for an additional 3 h at 37 C.
The supernates were added to C3-, factor B-, or factor D-deficient mouse
sera, and C3b uptake on zymosan granules was quantified by flow cytome-
try after staining with FITC-labeled polyclonal anti–mouse C3 (25). West-
ern blots were performed as described previously (22), see supplemental
Materials and methods.
Statistical analysis. Statistical analysis to determine differences between
groups for recall immune responses was performed using the Student’s t test.
P   0.05 was considered statistically significant.
Online supplemental material. Details of the methods for preparation
of lipid-tailed Daf and Western blots for complement components in cul-
ture supernatants are available online or from the author by request. Online
supplemental material is available at http://www.jem.org/cgi/content/full/
jem.20041967/DC1.
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